Prime Medicine (PRME) awards director 75,000 stock options at $3.06

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Prime Medicine, Inc. reported that director Kaye I Foster-Cheek received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036.

The 75,000 options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, subject to Foster-Cheek’s continuous service. Following this grant, the filing shows holdings of 75,000 derivative securities, with no open‑market buys or sells reported.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Foster-Cheek Kaye I

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	75,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 75,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 75,000 options Exercise price: $3.06 per share Option expiration: June 5, 2036 +2 more

5 metrics

Option grant size 75,000 options Stock Option (right to buy) granted to director on June 5, 2026

Exercise price $3.06 per share Conversion or exercise price for the 75,000 stock options

Option expiration June 5, 2036 Expiration date of the director’s stock option grant

Post‑grant derivative holdings 75,000 derivative securities Total shares following transaction as reported for the option grant

Vesting date trigger Earlier of June 5, 2027 or next annual meeting Full vesting schedule subject to continuous service

Key Terms

Stock Option (right to buy), exercise price, expiration date, derivative securities, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "3.0600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-05T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

derivative securities financial

"derivativeTransactionCount: 1, derivative securities position"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vesting financial

"The shares subject to this option shall vest in full upon the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/08/2026 - 04:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foster-Cheek Kaye I

(Last)

(First)

(Middle)

C/O PRIME MEDICINE, INC.

60 FIRST STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02141

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Prime Medicine, Inc. [ PRME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$3.06	06/05/2026		A		75,000		⁽¹⁾	06/05/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Remarks:

	/s/ Ryan Brown, attorney-in-fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Prime Medicine (PRME) disclose for Kaye I Foster-Cheek?

Prime Medicine disclosed a grant of 75,000 stock options to director Kaye I Foster-Cheek. These options give the right to buy common shares at a fixed price and represent compensation rather than an open‑market stock purchase or sale.

What are the key terms of the 75,000 stock options granted by Prime Medicine (PRME)?

The grant covers 75,000 stock options with an exercise price of $3.06 per share and an expiration date of June 5, 2036. The options allow the director to buy Prime Medicine common stock at that fixed price once vested.

When do the Prime Medicine (PRME) options for Kaye I Foster-Cheek vest?

The 75,000 options vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual stockholder meeting. Vesting is conditioned on Foster-Cheek’s continuous service to the company through the applicable vesting date.

Did the Prime Medicine (PRME) Form 4 show any stock sales or purchases?

The Form 4 shows a grant of derivative securities, not open‑market trades. It reports the award of 75,000 stock options to a director, with no common stock purchases or sales disclosed in this particular filing.

How many Prime Medicine (PRME) derivative securities does Kaye I Foster-Cheek hold after this grant?

After the reported grant, the filing lists 75,000 derivative securities for Kaye I Foster-Cheek. These represent the newly awarded stock options and reflect her position in this option grant following the transaction.